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ABSTRACT
Gene fusion is one of the hallmarks of cancer. Recent advances in RNA-seq of
cancer transcriptomes have facilitated the discovery of fusion transcripts. In this
study, we report identification of a surprisingly large number of fusion transcripts,
including six KANSARL (KANSL1-ARL17A) transcripts that resulted from the fusion
between the KANSL1 and ARL17A genes using a RNA splicingcode model. Five of
these six KANSARL fusion transcripts are novel. By systematic analysis of RNA-seq
data of glioblastoma, prostate cancer, lung cancer, breast cancer, and lymphoma from
different regions of the World, we have found that KANSARL fusion transcripts were
rarely detected in the tumors of individuals from Asia or Africa. In contrast, they exist
in 30 - 52% of the tumors from North Americans cancer patients. Analysis of CEPH/
Utah Pedigree 1463 has revealed that KANSARL is a familially-inherited fusion gene.
Further analysis of RNA-seq datasets of the 1000 Genome Project has indicated that
KANSARL fusion gene is specific to 28.9% of the population of European ancestry
origin. In summary, we demonstrated that KANSARL is the first cancer predisposition
fusion gene associated with genetic backgrounds of European ancestry origin.

are derived from gene fusion [1]. Since the genetic factors
identified so far only explain a small percentage of familial
cancer risks, discovery of novel genetic predisposition
factors for cancer is needed [5]. Fusion transcripts, which
can be derived from chromosomal rearrangements and
RNA processing events such as cis- and trans-splicing [6],
are of particular importance in that their products are able to
elicit immune responses in cancers and other diseases and
therefore may serve as cancer-specific antigens for cancer
vaccine development [7–15], a field that is currently drawing
extensive attention for cancer immunotherapy [7, 16–21].
Recent advances in RNA-seq have made it possible
to systematically analyze human cancer transcriptomes
for the discovery of fusion transcripts [10, 11, 22–25]. In

INTRODUCTION
Genetic predisposition to cancer has been well known
for several centuries initially through observation of unusual
familial clusterings, and later through identification of cancerprone families that demonstrate Mendelian inheritance of
cancer predisposition using different traditional techniques
such as comparative genomic hybridization [1–4]. Over 100
cancer predisposition genes (CPGs) have been identified,
including BRCA1 and BRCA2 in breast cancer, TP53 in
Li–Fraumeni syndrome, and APC in familial adenomatous
polyposis [1]. All these CPGs are derived from known
genes carrying point mutations; however, none of them
www.impactjournals.com/oncotarget
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of our approach, we selected KANSARL fusion transcripts
for systematic validation and characterization. We have
found that KANSARL fusion transcripts are associated
with multiple types of cancer. We have further shown that
KANSARL represents the first predisposition fusion gene
specific to the population of European ancestry origin.

recent years, RNA-seq data have grown exponentially, and
around 30,000 novel fusion transcripts and genes have been
identified thus far [26, 27]. The key challenge of using RNAseq to identify fusion transcripts lies in mapping RNA-seq
reads quickly and accurately to the reference genome [28].
Although enormous progress has been made and more than 30
software and algorithms have been developed for this purpose,
these systems are of low efficiency, sensitivity and accuracy
although great efforts have been made to improve [6, 29–32].
For example, Kinsella et al. have developed them a method
that allows to ambiguously map RNA-seq reads, and used it
to identify KANSL1-ARL17A (KANSARL) fusion transcripts
[33]. However, its fusion junction has turned out to be identical
to a cDNA clone [34]. Additionally, details about this fusion
that of transcript remain to be elusive, including its expression
patterns, relationship to somatic and germline mutations, and
association with cancer types and genetic backgrounds.
Both ARL17A and KANSL1 genes are located on
the reverse strand of the chromosome 17q21.31. KANSL1
encodes an evolutionarily-conserved nuclear protein, a
subunit of MLL1 and NSL1 complexes that is involved
in histone H4 acetylation and p53 Lys120 acetylation
[35]. KANSL1 ensures faithful chromosome segregation
during mitosis [36]. Two haplotypes of KANSL1 have been
described; the H1 and the inverted H2 forms of 17q21.31
polymorphism. Both contain independently derived, partial
duplications of the KANSL1 gene. These duplications have
recently arisen with high frequencies (26% and 19%) in the
population of European ancestry origin [37]. Some KANSL1
mutations have resulted in Koolen-de Vries syndrome
(KdVS) (OMIM #610443), characterized by developmental
delay, intellectual disability, hypotonia, epilepsy,
characteristic facial features, and congenital malformations
in multiple organs [38]. ARL17A gene encodes a protein
of the ARF family that is involved in multiple regulatory
pathways relevant to human carcinogenesis [39].
Previously, we have reported that recently gained
human spliceosomal introns have a signature of identical 5’
and 3’ splice sites [40]. Based on this finding, we have found
that both 5’ exonic sequences (E5) immediately upstream
of introns and 3’ intronic sequences near the 3’ splice site
(I3) are dynamically conserved among different lineages of
eukaryotic introns. The conservation is reminiscent of selfsplicing group II introns and of constraints imposed by base
pairing between intronic-binding sites (IBSs) and exonicbinding sites (EBSs) [40]. Therefore, we propose that both
E5 and I3 sequences constitute splicing codes, which are
deciphered by as-yet-to-be characterized splicer proteins/
RNAs via base-pairing [40]. Using this splicingcode model,
we developed a computational tool for analyzing RNA-seq
datasets in order to study gene expression pattern, and to
identify novel splicing isoforms and fusion transcripts.
In this study, we have used this software system
to analyze RNA-seq data from a variety of cancer types,
and identified over 1 million fusion transcripts of unique
splice junctions. To verify the reliability and robustness
www.impactjournals.com/oncotarget

RESULTS
Development of a computational high
throughput tool, SCIF (SplicingCodes Identify
Fusion Transcripts), for identification of fusion
transcripts
To develop an improved computational program
for identification of fusion transcripts, we first generated
a human splicingcode table as described previously [40,
41]. Supplementary Figure 1 shows the flowchart of using
the human splicingcode to identify fusion transcripts from
human RNA-seq data. After removal of highly-repetitive
sequences, poor quality sequences, and duplicated
sequences, we reduced our collection of introns from
382,279 to 230,000, the majority of which are unique. To
identify fusion transcripts, we selected 20-bp sequences
as key length, and screened our 230,000 pairs of 5’ and 3’
exonic keys. To improve the alignment accuracy and speed,
we have added an important step to continue sequence
alignments, that is, the sequences upstream of the 5’ key and
downstream of the 3’ key of the RNA-seq read were further
aligned to the corresponding genomic region of 5’ and 3’
exons. Supplementary Figure 2 shows that the 5’ region
of an RNA-seq read is identical to the 5’ exonic key from
Gene A, and its immediately downstream sequences were
aligned to the 3’ exonic key of Gene B. If both remaining
regions are identical to the corresponding genomic regions,
this read was then blasted against AceView human mRNAs/
EST database and the human gene database containing 20kb upstream sequences of 5’ genes and 20-kb downstream
sequences of 3’ genes, to remove sequences from
pseudogenes, gene duplications and alternatively-spliced
sequences. If blasted results confirmed that the RNA-seq
read was originated from two different regions or genes,
this read was deemed as a fusion transcript. To minimize
potential errors, we randomly generated exon-exon and
exon-intron chimeric sequence datasets to check artificial
exon-exon and exon-intron chimeric sequences. We
analyzed over 20,000 million of 75-101 bp RNA-seq reads,
and did not find a single copy of such random chimeric
sequences, suggesting that the artifacts generated during the
experiments have been reduced to close to zero. Because our
system requires that both 5’ and 3’ keys of fusion transcripts
are in the splicingcode table and their remaining sequences
are identical to the corresponding genomic sequences of the
keys, this approach allows us to remove poor-quality and
repetitive reads quickly and to have a very fast speed in
aligning the entire reads to their genomic targets with much
50595
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higher accuracy. Consequently, based on the lengths of
identical sequences, we found that the maximum of random
error to generate a fusion transcript was 1.2 × 10-24 and the
medium error was 1 × 10-59. We have named this program
SCIF (SplicingCodes Identify Fusion Transcripts).

were downloaded from the ENCODE project [42]. We
identified a total of 92,817 fusion transcripts with unique
fusion junctions. We then selected KANSARL fusion
transcripts for further investigation. The existence and
abundances of multiple KANSARL isoforms in cells ruled
out the possibility that KANSARL fusion transcripts are
trans-spliced products. The ARL17A and KANSL1 genes
consist of 11 and 16 exons, respectively (Figure 1A). An
inverted genomic structure of KANSL1→ARL17A gene
order to generate KANSARL fusion transcripts results
from putative inversions or duplications of the normal

Identification of KANSARL fusion transcripts
We first used the above approach to analyze
37,208 millions of RNA-seq reads from 39 cancer
cell lines (designated as ECD39), majorities of which

Figure 1: Identification and characterization of KANSARL (KANSL1-ARL17A) fusion transcripts. (A) A schematic

diagram showing steps of genetic rearrangements from normal genomic structures of ARL17A → KANSL1 genes to inverted genomic
structures of KANSL1 → ARL17A genes on the chromosomal band 17q21.31. Dashed white horizontal arrow and solid white vertical
arrow represent genomic rearrangements and potential fusion gene structures. Solid red and black horizontal arrows indicate ARL17A and
KANSL1 genes, respectively. Solid blue arrows represent LRRC37A and MAPT genes, respectively. The dashed horizontal black arrow
indicates undetermined genomic regions. Black and black squares represent KANSL1 and ARL17A exons respectively. (B) The schematic
diagram shows KANSARL fusion transcripts identified so far. Black and red squares represent KANSL1 and ARL17A exons respectively.
Dashed lines indicate omitted regions. The numbers above the black and red squares are exon numbers. The numbers within sequences
indicate omitted numbers of nucleotides; (C) Validation of KANSARL isoform 1 in A549, HeLa, K562, 786-O and OS-RC-2 cell lines; (D)
Validation of KANSARL isoform 2 in A549, HeLa, K562, 786-O and OS-RC-2 cell lines; (E) Detection of KANSL1 gene expression in
A549, HeLa, K562, 786-O and OS-RC-2 cell lines; (F) Detection of ARL17A gene expression in A549, HeLa, K562, 786-O and OS-RC-2
cell lines; (G) Detection of GAPDH gene expression as loading controls in A549, HeLa, K562, 786-O and OS-RC-2; (H) Sanger sequencing
validation of KANSARL isoform 2. The black and red letters represent KANSL1 exon 3 and ARL17A exon 3 sequences, respectively. And
(I) Sanger sequencing validation of KANSARL genomic breakpoint in the Hela-3 cell line. The black and red letters indicate KANSL1
and ARL17A intronic sequences, respectively. Vertical arrows indicate the fusion junctions. The black and red lines indicate KANSL1 and
ARL17A sequences, respectively. All markers are 100 bp DNA markers.
www.impactjournals.com/oncotarget
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genomic structure, ARL17A→ KANSL1 (Figure 1A).
Figure 1B and Supplementary Table 1 show that the six
KANSARL isoforms 1 to 6 identified in ECD39 datasets.
In these six KANSARL isoforms, KANSL1 gene uses three
splice junctions of exons 2, 3, and 6, indicating that the
5’ breakpoint occurred at least downstream of the exon
2. ARL17A retains exons 3, 4, 7, and 8, indicating that
the 3’ breakpoint occurred upstream of the ARL17A exon
3 (Figure 1B). It is notable that only KANSARL isoform
2 among these six KANSARL isoforms was identified
previously [33, 34], and the other five isoforms are novel.
Supplementary Figure 3 shows that the six KANSARL
fusion transcripts encode putative peptides with 437,
483, 496, 505, 450, and 637 amino acids, respectively.
The majority of these peptide sequences were derived
from KANSL1 gene. Thus, these putative KANSARL
fusion peptides are similar to those derived from KANSL1
truncated mutants and retain only coiled-coil domain,
while lost the WDR5 binding region, Zn finger, the
domain for KAT8 activity, and PEHE [38].

To further validate the KANSARL genomic
breakpoint, we have also performed analysis of whole
genome shotgun (WGS) data from KANSARL-positive
individuals of CEPH/Utah Pedigree 1463 and results
indicated that the genomic breakpoints are located at
KANSL1 intron 3 and ARL17A intron 2 (Supplementary
Figure 5). Then, we have isolated genomic DNA from Hela3 cells and performed genomic amplification using the
primers gKANSL1F1 and gARL17AR1 (Supplementary
Table 4). Supplementary Figure 6 shows the PCR product,
which was then recovered for direct DNA sequencing
(Supplementary Figure 7). DNA analysis and manual
inspection have located the breakpoint of KANSL1 intron
3 and ARL17A intron 2 (Figure 1I), and indicated that the
PCR product contains the identical genomic breakpoint
sequences of the H1 form of the 17q21.31 inversion
polymorphism reported previously [43]. Thus, we
have validated the KANSARL fusion breakpoint at both
RNA and genome levels and derived from the 17q21.31
inversion polymorphism reported previously [43].

Experimental validation of KANSARL fusion
transcripts and genomic breakpoint

Characterization of the expression patterns of
KANSARL fusion transcripts in ECD39 cancer
cell lines

We next aimed to validate KANSARL fusion
transcripts shown in Figure 1B. To this end, we used
A549, HeLa, and K562 cells, which are positive for
KANSARL fusion transcripts in RNA-seq datasets
(Supplementary Table 2), for RT-PCR and sequencing
analyses, and cell lines 786-O and OS-RC-2 were used
as negative controls. Figure 1C shows that amplification
of A549, HeLa, and K562 cDNAs using the primer pair
KANSARLISOF1 and KANSARLISOR1 generated PCR
fragments with the expected size 379-bp (Supplementary
Table 4). Direct Sanger DNA sequencing of the cloned
PCR fragments confirmed that they have the correct fusion
junction of KANSARL fusion isoform 1 (Supplementary
Figure 4). Figure 1D shows that PCR using the primer
pairs KANSARLF1 and KANSARLR1 (Supplementary
Table 4) produced fragments with the expected size
431-bp. Sequencing analysis shows that these fragments
contain the expected fusion junction of KANSARL isoform
2 (Figure 1H), which was reported previously [33, 34].
Overall, we have shown that both KANSARL isoforms 1
and 2 contain the correct fusion junction sequences.
To better understand KANSARL fusion events, we
performed RT-PCR analysis for KANSL1 and ARL17A
expression using primers overlapping breakpoints of
KANSL1 and ARL17A genes (Supplementary Table 4)
in KANSARL-positive (A564, HeLa, and K562) and
KANSARL-negative (786-O and OS-RC-2) cell lines.
Figure 1E&1F show that the expression patterns of
KANSL1 and ARL17A genes in A564, HeLa, and K562
are very similar to those in 786-O and OS-RC-2. Figure
1G shows the expression levels of GAPDH gene that
were used as loading controls.
www.impactjournals.com/oncotarget

As shown in Supplementary Table 2, 11 out of
39 (29%) cancer cell lines express KANSARL fusion
transcripts, suggesting that KANSARL is a highly-recurrent
fusion gene. To verify this claim, we performed RT-PCR
analysis for a pool of uncharacterized breast cancer and
lymphoma cell lines. Figure 2A shows that among 10
breast cancer cell lines, HCC-1937, T47D, MAD-436, and
SUM-157 cells express KANSARL isoform 2. Figure 2B
shows that among the eight lymphoma cell lines, DHL5, DHL-8, OCI-Ly10, and Val express KANSARL isoform
2. Figure 2C&2D show that all the eight lymphoma
cell lines have at least one copy of KANSL1 gene and
one copy of ARL17A gene. Thus, the results show that
KANSARL fusion transcripts exist in cancer cell lines at
high frequencies.
To further investigate the differential expression
of these six individual KANSARL isoforms in cancer cell
lines, we analyzed their relative abundance of in ECD39
dataset [42]. Figure 3A and Supplementary Table 1
show the distribution of raw counts of the six KANSARL
fusion transcripts, among which KANSARL isoform 2 is
the most abundant, and is 50-fold and 1,216-fold greater
than isoforms 1 and 3, respectively. Supplementary Table
2 shows that KANSARL fusion transcripts were detected
in 11 out of 39 cancer cell lines, including A375, A549,
G401, H4, HeLa-3, HT29, K562, Karpas422, M059J, OCILy7, and SK-N-DZ. In contrast, we have not identified a
single copy of KANSARL fusion transcript in the rest of
28 cell lines, among which HepG2 has the largest number
(over 1,200 million) of RNA-seq reads analyzed so far,
suggesting that the depths of RNA-seq reads have no
50597
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and 1.28% of the GAPDH expression levels in A549,
HeLa, and K562, respectively, while KANSARL isoform
1 is expressed only at 0.0056%, 0.0037% and 0.015%
of the GAPDH expression levels in the same cell
lines (Supplementary Table 3). Figure 3C shows that
KANSARL isoform 2 is expressed at 64 to 83 fold higher
than KANSARL isoform 1. The differential expression
patterns between these two KANSARL isoforms detected
using real-time PCR are generally consistent with that
obtained from RNA-seq data analysis (Supplementary
Table 1).

impacts on our analysis outcomes. To normalize for a total
number of reads, we adjusted our values relative to the
number of splice junctions per million reads (NSJMR). We
found that all the 11 cell lines express KANSARL isoform
2 (Figure 3B), and different expression levels of the other
five isoforms. Karapas-422, A549, H4, HT29, A375, SKN-SH, and K562 cells are among the cancer cell lines with
the highest levels of KANSARL fusion transcripts, and are
more than 7-fold on average than the other four cell lines.
Quantitative real-time PCR results indicate that
KANSARL isoform 2 is expressed at 0.36%, 0.28%

Figure 2: RNA-typing of KANSARL fusion transcripts in breast and lymphoma cancer cell lines. Detections of KANSARL
transcripts were evaluated by RT-PCR with the primers shown in Supplementary Table 4. (A) breast cancer cell lines; (B) lymphoma cell
lines. (C) Detection of KANSL1 gene expression; (D) Detection of ARL17A gene expression; and (E) Detection of GAPHD gene expression
as controls. All markers are 100bp DNA markers;
www.impactjournals.com/oncotarget
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KANSARL fusion transcripts are expressed
predominantly in cancer patients with European
ancestry origin

samples from 27 glioblastoma patients and 17 non-neoplastic
brain tissues [44]. Figure 4A and Supplementary Table 5 show
that 14 of the 27 (51.9%) GBM patients express KANSARL
fusion transcripts. In contrast, KANSARL fusion transcripts
were detected only in 2 out of 17 (or 11.8%) non-neoplastic
brain tissues. The difference in the expression frequencies of
KANSARL fusion transcripts between glioblastomas and nonneoplastic persons is statistically significant (Supplementary
Table 5, Fisher’s exact test, p<0.01; Figure 4A), indicating
that KANSARL fusion transcripts are preferentially associated
with diffuse glioblastomas.

Since Supplementary Table 2 shows that KANSARL
fusion transcripts are expressed in brain cancer cell lines
including H4, MJ059 and SK-N-DZ, we were prompted
to identify and characterize KANSARL fusion transcripts in
glioblastomas. To this end, we analyzed the glioblastoma
RNA-seq dataset from Columbia University Medical Center,
New York (designated as CGD), which has a total of 94

Figure 3: Characterization of KANSARL isoform expression in ECD39 cell lines, A549, HeLa and K562. (A) Distribution

of raw counts of the six KANSARL isoforms identified in the ECD39 datasets; (B) Normalization of raw counts into NSJMR (Numbers of
Splice Junctions per Million) of KANSARL fusion transcripts among the KANSARL-positive cancer cell lines. Y-axis shows Numbers of
Splice Junctions per Million Reads (NSJMR). (C) Quantification of KANSARL isoform 1 and 2 of A549, HeLa and K562 by real-time PCR
with the primers shown in Supplementary Table 4. The raw real-time RT-PCR data of KANSARL isoform 1 and 2 of A549, HeLa and K562
are listed in Supplementary Table 3.
www.impactjournals.com/oncotarget
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To further investigate KANSARL fusion transcripts
in glioblastomas, we performed a comparative expression
analysis of the glioblastomas dataset deposited by Beijing
Neurosurgical Institute, Beijing, China (designated as
BGD), which has 272 gliomas of different clinic prognosis
stages [45]. Surprisingly, only two out of the 272 BGD
glioblastoma samples (less than 1%) are KANSARL
positive (Figure 4B). Thus, KANSARL positivity in BGD
glioblastoma is 70 fold lower than that in the CGD dataset.
Supplementary Table 6 shows that the difference between
CGD and BGD is statistically significant (Fisher’s exact
test, p<0.001).
The dramatic difference in the expression
frequencies of KANSARL fusion between the CGD and

BGD datasets has raised the possibility that KANSARL
fusion transcripts are associated with cancer patients
of European ancestry origin. To confirm this claim, we
performed comparative analyses of RNA-seq datasets
in more types of cancers, including prostate cancer,
breast cancer, lung cancer and lymphoma from different
geological regions of the World (see detailed analysis in
Supporting Data). Our results show that KANSARL fusion
transcripts were rarely found in the tumor samples from
Asia and Africa, but were detected in 30~52% of cancer
samples from patients in North America. Therefore,
we conclude that KANSARL fusion transcripts are
preferentially associated with tumor samples from patients
with European ancestry origin.

Figure 4: Systematic analyses of KANSARL fusion transcripts in glioblastomas. (A) Analysis of KANSARL fusion transcripts
in the CGD glioblastoma RNA-seq datasets. “Normal” and “Gliomas” represented brain tissues of non-neoplastic donors and diffuse
glioblastomas (GBM) patients, respectively. (B) Comparative analysis of KANSARL fusion transcripts between the BGD and CGD
datasets that consist of 272 glioblastoma patients from Beijing Neurosurgical Institute, Beijing, China, and 27 glioblastoma patients of
Columbia University Medical Center, New York, USA, respectively. Comparative analyses of prostate cancer, lung cancer, breast cancer
and lymphomas from different geological regions of the World are shown in Supporting Materials.
www.impactjournals.com/oncotarget

50600

Oncotarget

KANSARL fusion transcripts are associated
with prostate cancer biomarker TMPRSS2-ERG
fusion transcripts in prostate cancer

KANSARL fusion transcripts, suggesting that KANSARL
fusion transcripts may be involved in epigenetic
alternations in early stages of cancer development.

In supporting data, analysis of 25 high-risk prostate
tumors from Vancouver Prostate Center, Vancouver,
Canada (VPD) [46] has shown that 13 of them (52%)
have KANSARL fusion transcripts. We have also found
that KANSARL and TMPRSS2-ERG are the two most
highly-expressed fusion genes in the VPD prostate
cancer dataset. These observations suggest a possible
relationship between KANSARL fusion transcripts and
somatic TMPRSS2-ERG fusion transcripts. We have
further shown that TMPRSS2-ERG fusion transcripts
are expressed in 15 out of 25 prostate tumors, consistent
with the notion that TMPRSS2-ERG fusion transcripts
are prostate cancer biomarkers [46]. Figure 5 and
Supplementary Table 7 show that 13 out of 15 TMPRSS2ERG-positive prostate tumors are KANSARL-positive, and
100% KANSARL-positive prostate tumors express somatic
TMPRSS2-ERG fusion transcripts. In contrast, only two
TMPRSS2-ERG-positive prostate tumors were detected
in 12 KANSARL-negative prostate tumors. The difference
of TMPRSS2-ERG fusion transcripts between KANSARLpositive and KANSARL-negative tumors is significant
(Supplementary Table 7, Fisher’s exact test, p<0.001),
indicating that KANSARL fusion transcripts are associated
with prostate cancer biomarker TMPRSS2-ERG fusion
transcripts in the VPD tumor patients.
Furthermore, Supplementary Table 8 shows that
the prostate and breast cancers with KANSARL fusion
transcripts have increased the numbers of recurrent readthrough (epigenetic) fusion transcripts than those without

KANSARL fusion gene is familially inherited and
may be ubiquitously expressed in KANSARLbearing individuals
The presence of KANSARL fusion transcripts in
normal and adjacent tissues in CGD and VPD raised the
possibility that KANSARL fusion transcripts are derived
from a germline-inherited fusion gene. To investigate this
possibility, we performed RNA-seq data analysis for the
lymphoblastoid cell lines derived from the families in the
CEU population (CEPH/Utah Pedigree 1463, Utah residents
with ancestry from northern and western Europe), which
includes a three-generation family with 17 individuals
[47]. Supplementary Table 9 and Supplementary Figure 8
show that KANSARL fusion transcripts were detected in 15
of 17 family members, as indicated by black squares and
circles in Supplementary Figure 8, except son (NA12885),
which is deviated from the first Mendel law. A reasonable
explanation is that the grandfather sample (NA12889)
might have been mixed with the son sample (NA12885).
To prove this possibility, we performed analyses of
the WSG data (PRJEB3381) and RNA-seq from 1000
Genome Project, and shown that both WSG and RNA-seq
of grandfather sample (NA12889) are KANSARL-negative
while WGS of the son (NA12885) is KANSARL-positive
(Supplementary Table 10). Supplementary Table 10
shows the genomic breakpoint 1 and 2 of the KANSARL
fusion gene (Supplementary Figure 5 and 9) identified by
analysis of WGS data among some members of CEPH/

Figure 5: Relationship between KANSARL fusion transcripts and somatic TMPRSS2-ERG fusion transcripts in VPD
prostate tumors. The dataset VPD has 25 prostate patient samples from Vancouver Prostate Centre [46]. KANSARL+ and KANSARL-

represented KANSARL-positive and KANSARL-negative tumor samples, respectively. TMPRSS2-ERG fusion gene is the predominant
molecular subtype of prostate cancer.
www.impactjournals.com/oncotarget
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Utah Pedigree 1463. Therefore, Both WGS and RNAseq data support that the father (NA12877) and the
mother (NA12878) have the genotypes of KANSARL/KANSARL- and KANSARL+/KANSARL+ respectively and
all their offsprings are the genotype KANSARL+/KANSARL(Figure 6A).
As shown above, KANSARL is a familiallyinherited fusion gene. A critical question was then whether
KANSARL fusion transcripts exist in general populations.
To answer this question, we analyzed RNA-seq data of

the lymphoblastoid cell lines of the 1000 Genome Project
[48]. Supplementary Table 11 shows that no single copy
of KANSARL fusion transcripts has been detected in the
Nigeria YRI (Yoruba in Ibadan) population. In contrast,
Figure 6B and Supplementary Table 11 show that
KANSARL fusion transcripts have been found in 33.7%
GBR (British from England and Scotland), 26.3% FIN
(Finnish in Finland) and 26.9% TSI (Toscani in Italia)
populations, respectively. The differences of KANSARL
frequencies among the GBR, FIN, and TSI population are

Figure 6: Inheritance and distribution of KANSARL fusion transcripts in the population of European ancestry origin.

(A) Diagrams of correct KANSARL inheritance in the CEPH/Utah Pedigree 1463, which includes four grandparents, two parents, and eleven
children. Black and white squares represent KANSARL-positive and KANSARL-negative males while black and white squares indicate
KANSARL-positive and KANSARL-negative females. The black lines represent relationships among the family members. The diagram is
drawn based on RNAs-seq and WGS data. (B) Analysis of KANSARL fusion transcripts in the RNA-seq data of the lymphoblastoid cell
lines of the 1000 Genome Project [48]. The diagram shows frequencies of KANSARL fusion transcripts in some populations of European
and African ancestries. GBR is British from England and Scotland; FIN indicates Finnish in Finland; TSI represents Toscani in Italia, and
YRI is Yoruba in Ibadan, Nigeria.
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not statistically significant (data not shown), suggesting
that these differences may be caused by sampling errors.
However, their differences with that of Nigeria YRI
are statistically significant (Supplementary Table 11,
Fisher’s exact test, p<0.001), confirming our claim that
KANSARL fusion transcripts are specific to the population
of European ancestry origin.
As Supplementary Table 2 shows, KANSARL fusion
transcripts are expressed in many tissues and organs
in KANSARL-bearing individuals. To systematically
understand the patterns of KANSARL gene expression
in human tissues, we analyzed RNA-seq datasets from
Science for Life Laboratory, Sweden (designated as
SSTD), which are originated from 32 different tissue
samples of 127 healthy individuals [49]. Supplementary
Table 12 shows that KANSARL fusion transcripts are
detected in 28 of 32 tissues analyzed, except bone
marrow, kidney, stomach and smooth muscle. These data
suggest that KANSARL fusion transcripts are ubiquitously
expressed in the tissues and organs of KANSARL-bearing
individuals.

as shown in Supplementary Figure 2. A desktop computer
with a core of i5 and 8 GB memory can process 25~120
millions of RNA-seq reads per hour since validation times
used by BLAST constitute up to 80% of the computation
costs and are highly variable. The SCIF software can
detect a single copy of a given fusion transcript to over
10,000 fusion transcripts per sample.
In our practice, to generate consistent KANSARL
data, we have set the minimum 20 million RNA-seq
reads for KANSARL analysis. These quality controls have
greatly increased data reproducibility and minimized
misalignment errors to false positivity less than 1%. For
example, the CGD 27 glioblastoma dataset includes 39
CE samples and 36 NE sequencing samples that were
effectively constituted as multiple duplicate experiments
in the context of KANSARL fusion transcripts [44].
All KANSARL-positive samples were detected in the
corresponding CE and NE samples and the duplicate
samples, and all KANSARL-negative samples are also
reproducible in analysis results. That is, analysis results of
100% of both KANSARL-positive and KANSARL-negative
samples can be reproducible, indicating that our approach
is reliable.
Moreover, analysis of the VPD prostate cancer
RNA-seq dataset using SCIF has identified 16 TMPRSS2ERG fusion transcripts (rearrangements), 11 of which are
novel (manuscript in preparation). Thus, our technology
overcomes the major challenges and limitations in
previous techniques, and provides a powerful tool for
detection of low-level fusion transcripts that can serve as
biomarkers for early cancer diagnosis [6].

DISCUSSION
In this study, we have developed and used our high
throughput computational system SCIF to systematically
analyze KANSARL fusion transcripts in a variety of
cancer and normal samples with high capacity, high
sensitivity, high accuracy and much lower computation
time consumption. Our results demonstrate that KANSARL
fusion transcripts are derived from a cancer predisposition
fusion gene specific to the population of European
ancestry origin.

KANSARL fusion gene is associated with
polymorphism of the chromosomal band 17q21.31

Technical improvements for profiling fusion
transcripts from RNA-seq datasets

The identical fusion junction of KANSARL fusion
transcripts and genomic breakpoint of the KANSARL fusion
gene (Figure 1H and Supplementary Figure 7) with those
from the H1 form of 17q21.31 inversion polymorphism
suggest that KANSARL fusion transcripts are derived
from the H1 form of 17q21.31 inversion polymorphism,
which counts for 26% population of European ancestry
origin [43]. Since we have excluded the data from Utah
residents with ancestry from northern and Western Europe
like those of CEPH/Utah Pedigree 1463, average 28.9%
KANSARL fusion transcripts in population of European
ancestry origin are much higher than 26% of the H1 form
[43]. One of possibilities is that complexities of duplications
make it difficult to perform accurate analysis of WGS data
and result in lower numbers of the H1 form. The second
possibility is that additional genomic breakpoints exist
in the chromosomal band 17q21.31. The presence of the
putative genomic breakpoint 2 of KANSARL fusion gene
in the CEPH/Utah Pedigree 1463 supports this possibility
(Supplementary Figure 9 and Supplementary Table 10).
However, the additional KANSARL genomic breakpoint

Chimeric RNAs are well known to be generated
from
chromosomal
rearrangements,
including
translocations, deletions, and inversions. Recently, transsplicing and cis-splicing of read-through pre-mRNAs
between adjacent genes have been shown as emerging
mechanisms for their generation [6]. Intergenically spliced
fusion transcripts, which could be present at low levels in
a given cancer type, represent a new repertoire of cancerspecific biomarkers for early cancer detection, and also
have potential applications in cancer diagnosis, prognosis,
and therapeutic design [6, 28].
The major obstacles to analyze RNA-seq data--“Big
Data” are to map reads to the genome with high efficiency
and accuracy. As shown in Supplementary Figure 1, to
improve accuracy and efficiency, first, SCIF has directly
mapped raw sequences of RNA-seq reads to the human
genomes instead of clustering. Secondly, SCIF has directly
extended their flanking sequence alignments after partial
sequences of a read were mapped to two different genes,
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will be required for further confirmation. This uncertainty
of the putative KANSARL fusion genomic breakpoints
suggests that RNA-typing of KANSARL fusion transcripts
will provide more accurate data than DNA-typing of the
KANSARL genomic breakpoints.

by vortex vigorously for 15 seconds and the mixes were
incubated at room temperature for 2-3 min. The samples
were then centrifuged at 4,000 g for 15 min to separate
the mixtures into a lower red, phenol-chloroform phase
and a colorless upper aqueous phase. RNA in the aqueous
phase was precipitated by mixing with 0.5 volumes of
isopropyl alcohol for 10 min, and then centrifuging at
12,000 g for 10 min at room temperature. The RNA pellet
was washed twice with 1 ml of 75% ethanol, air-dried, and
then dissolved in 40-80 μl of RNase-free H2O. The organic
phase was saved for isolation of DNA or protein.

KANSARL as the first cancer predisposition
fusion gene that may play crucial roles in
tumorigenesis
We have provided solid evidence, for the first
time, supporting that the KANSARL fusion transcripts
are associated with multiple types of cancer, including
glioblastomas, prostate, breast cancer, lung cancer and
lymphomas. KANSARL fusion transcripts have been
detected in healthy individuals of European ancestry
origin and are familially-inherited. These results support
our claim that KANSARL is a cancer predisposition fusion
gene specific to populations of European ancestry origin.
In all analyzed datasets, we have detected KANSARL
fusion transcripts in all samples with KANSARL fusion gene,
and the isoforms 1 and 2 have significantly higher expression
levels in cancer patients compared to healthy individuals in
general. However, isoforms 3-6 are expressed at very low
levels and their differences cannot be determined.
All the six putative fusion peptides encoded by
KANSARL fusion transcripts lack some functional
domains, and therefore cancer patients expressing
KANSARL fusion transcripts would display reduced
activities of the histone acetyltransferase KAT8 and
p53 [50–52]. It is quite possible that the reduction of
KAT8 and p53 activities results in hypermutations in
certain chromosomal regions of cancer cells and/or
epigenetic changes that generate new read-through fusion
transcripts, as shown in Supplementary Table 8. Since
KANSARL-bearing cancer patients may be not sensitive
to histone deacetylase inhibitors (HDACis) due to lower
histone acetylation, KANSARL-negative patients may be
respond well to treatments of HDACis.
In summary, our results demonstrate that KANSARL
fusion gene exists in many types of cancer and is the
first novel germline fusion gene specific to the genetic
backgrounds of European ancestry origin. Our research
provides an example to use our SCIF system for discovery of
novel fusion transcripts that may play underappreciated but
crucial roles in tumorigenesis and have promising therapeutic
applications by serving as cancer biomarkers, drug targets, or
specific epitopes for cancer vaccine development.

cDNA synthesis
The first-strand cDNA synthesis was carried out
using oligo(T)15 and/or random hexamers using TaqMan
Reverse Transcription Reagents (Applied Biosystems Inc.,
Foster City, CA, USA) as suggested by the manufacturer.
In brief, to prepare 2× RT master mix, we pooled 10 μl
of reaction mixes containing final concentrations of 1X
RT Buffer, 1.75 mM MgCl2,, 2 mM dNTP mix (0.5 mM
each), 5 mM DTT, 1X random primers, 1.0 U /μl RNase
inhibitor and 5.0 U/μl MultiScribe reverse transcriptase.
10 μl of total RNAs (2 μg) were mixed well with 10 μl of
2X master mixes. The reaction mixes were then placed in
a thermal cycler for 10 min at 25oC, 120 min at 37oC, and
then for 5 min at 95oC. The resulted cDNAs were diluted
with 80 μl H2O.

End-point PCR amplification
To identify novel human fusion transcripts, specific
primers were designed to match the 5’ and 3’ ends of a
given fusion transcript, using a primer-designing software
[53]. 5 μl of the cDNAs generated above were used as
template for end-point PCR, which was carried out using
HiFi Taq polymerase (Invitrogen, Carlsbad, CA, USA) for
35 cycles of 94°C for 15”, 60-68°C for 15” and 68°C for
2-5 min. The PCR products of KANSARL isoforms 1 and 2
were separated on 2% agarose gels, recovered and cloned
into TOPO pCR2.1 vector as suggested by manufacturer.
After transformation and incubation at 37oC overnight,
the plasmids with inserts were isolated and sequenced.
The sequences were then verified by blast and manual
inspection. For genomic fusion validation, genomic DNA
from HeLa-3 cells was used as template for end-point
PCR using the Phusion PCR kit (NEB), with an annealing
temperature at 60°C.

Quantitative real-time PCR

MATERIALS AND METHODS

To quantify expression levels of different KANSARL
isoforms, isoform-specific primers were designed using
a primer-designing software [53]. 5 μl of the cDNAs
generated above were used as template for real-time PCR,
which was carried out using SYBR Green PCR Master
Mix (Roche) on a LightCycler 480II system (Roche) as

Isolation of total RNAs from cell lines
Medium was removed from100-mm culture dishes
and 1 ml of Trizol reagent (Invitrogen, CA) was added
directly in each 100-mm culture dish. The cells were lysed
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the manufacturer suggested. For each reaction, 5 μl of
480 SYBR Green I Master Mix (2X), 2 μl of primers
(10X) and 3 μl of H2O were pooled into a tube and mixed
carefully by pipetting up and down. 15 μl of the PCR mix
were pipetted into each well of the LightCycler® 480
Multiwell Plate, and then mixed with 5 μl of cDNAs. The
plate was sealed, centrifuged at 1,500 g for 2 min, and then
transferred into the plate holder. The PCR was performed
for 45 amplification cycles.
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